Technology | April 09, 2026
Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
